In non-small-cell lung cancer (NSCLC), eGFR acts as a direct target of miRNA, and siRNA knockdown of EGFR can inhibit cell proliferation, promote apoptosis, and arrest cell-cycle progression. Here, EGFR is linked to non-small cell lung carcinoma.